Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

ImmuCell Corporation

Filed: Mar 12, 2026Portland, MaineCIK: 0000811641
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Steven A. Rosgen resigned from ImmuCell Corporation's Board of Directors effective April 1, 2026, and was replaced by Kathy V. Turner, who brings 30+ years of healthcare and animal health executive experience. This board transition reflects routine governance changes ahead of the company's 2026 Annual Meeting of Shareholders.

Key Takeaways

Steven A. Rosgen opted not to run for reelection and resigned from the Board effective April 1, 2026

Kathy V. Turner was elected to fill the vacancy, bringing over 30 years of global healthcare and animal health executive leadership experience

2 more takeaways

Related Filings (2)

2 more filings from ImmuCell Corporation in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 12, 2026
Item5.02
CategoryExecutive Change
CIK0000811641
Accession #0000811641
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board changeleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings